[{"address1": "500 North Beacon Street", "address2": "4th Floor", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 218, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 45, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 1226500, "exercisedValue": 1110312, "unexercisedValue": 37845672}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 754540, "exercisedValue": 703665, "unexercisedValue": 9900757}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 719400, "exercisedValue": 0, "unexercisedValue": 838368}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Noah  Goodman M.B.A.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 46.2, "open": 46.19, "dayLow": 45.8435, "dayHigh": 47.345, "regularMarketPreviousClose": 46.2, "regularMarketOpen": 46.19, "regularMarketDayLow": 45.8435, "regularMarketDayHigh": 47.345, "payoutRatio": 0.0, "beta": 2.177, "forwardPE": -15.109325, "volume": 579312, "regularMarketVolume": 579312, "averageVolume": 708419, "averageVolume10days": 703920, "averageDailyVolume10Day": 703920, "bid": 46.82, "ask": 47.14, "bidSize": 1, "askSize": 1, "marketCap": 3359672320, "fiftyTwoWeekLow": 19.445, "fiftyTwoWeekHigh": 53.27, "priceToSalesTrailing12Months": 75.14196, "fiftyDayAverage": 43.471, "twoHundredDayAverage": 38.56585, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2779941120, "profitMargins": 0.0, "floatShares": 46960337, "sharesOutstanding": 71497600, "sharesShort": 8164580, "sharesShortPriorMonth": 7754994, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.1142, "heldPercentInsiders": 0.02525, "heldPercentInstitutions": 1.09986, "shortRatio": 12.97, "shortPercentOfFloat": 0.1409, "impliedSharesOutstanding": 71497600, "bookValue": 13.769, "priceToBook": 3.4127388, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -275433984, "trailingEps": -3.49, "forwardEps": -3.11, "enterpriseToRevenue": 62.176, "enterpriseToEbitda": -9.113, "52WeekChange": -0.0307343, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 46.99, "targetHighPrice": 88.0, "targetLowPrice": 53.0, "targetMeanPrice": 62.21053, "targetMedianPrice": 60.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 665444992, "totalCashPerShare": 9.307, "ebitda": -305056000, "totalDebt": 85714000, "quickRatio": 8.059, "currentRatio": 8.32, "totalRevenue": 44711000, "debtToEquity": 8.823, "revenuePerShare": 0.564, "returnOnAssets": -0.19919, "returnOnEquity": -0.33257, "grossProfits": -246159008, "freeCashflow": -153841376, "operatingCashflow": -251008000, "revenueGrowth": -0.553, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.36816, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1598016600000, "postMarketChangePercent": 2.1493897, "postMarketPrice": 48.0, "postMarketChange": 1.0099983, "regularMarketChange": 0.790001, "regularMarketDayRange": "45.8435 - 47.345", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 708419, "fiftyTwoWeekLowChange": 27.545002, "fiftyTwoWeekLowChangePercent": 1.4165597, "fiftyTwoWeekRange": "19.445 - 53.27", "fiftyTwoWeekHighChange": -6.279999, "fiftyTwoWeekHighChangePercent": -0.11788997, "fiftyTwoWeekChangePercent": -3.07343, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "earningsCallTimestampStart": 1754915400, "earningsCallTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.49, "epsForward": -3.11, "epsCurrentYear": -3.39273, "priceEpsCurrentYear": -13.8502035, "fiftyDayAverageChange": 3.519001, "fiftyDayAverageChangePercent": 0.08095054, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1757717846, "regularMarketTime": 1757707201, "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "market": "us_market", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "regularMarketChangePercent": 1.70996, "regularMarketPrice": 46.99, "twoHundredDayAverageChange": 8.424152, "twoHundredDayAverageChangePercent": 0.21843554, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]